SEARCH

SEARCH BY CITATION

References

  • 1
    Holgate S, Casale T, Wenzel S, Bousquet J, Deniz Y, Reisner C. The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. J Allergy Clin Immunol 2005;115:459465.
  • 2
    Burrows B, Martinez FD, Halonen M, Barbee RA, Cline MG. Association of asthma with serum IgE levels and skin-test reactivity to allergens. N Engl J Med 1989;320:271277.
  • 3
    Pollart SM, Chapman MD, Fiocco GP, Rose G, Platts-Mills TA. Epidemiology of acute asthma: IgE antibodies to common inhalant allergens as a risk factor for emergency room visits. J Allergy Clin Immunol 1989;83:875882.
  • 4
    Platts-Mills TA. The role of immunoglobulin E in allergy and asthma. Am J Respir Crit Care Med 2001;164:S1S5.
  • 5
    Stokes J, Casale TB. Rationale for new treatments aimed at IgE immunomodulation. Ann Allergy Asthma Immunol 2004;93:212217.
  • 6
    Presta LG, Lahr SJ, Shields RL, Porter JP, Gorman CM, Fendly BM et al. Humanization of an antibody directed against IgE. J Immunol 1993;151:26232632.
  • 7
    MacGlashan DW Jr, Bochner BS, Adelman DC, Jardieu PM, Togias A, McKenzie-White J et al. Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol 1997;158:14381445.
  • 8
    Prussin C, Griffith DT, Boesel KM, Lin H, Foster B, Casale TB. Omalizumab treatment downregulates dendritic cell FcepsilonRI expression. J Allergy Clin Immunol 2003;112:11471154.
  • 9
    Noga O, Hanf G, Brachmann I, Klucken AC, Kleine-Tebbe J, Rosseau S et al. Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma. J Allergy Clin Immunol 2006;117:14931499.
  • 10
    Boulet LP, Chapman KR, Cote J, Kalra S, Bhagat R, Swystun VA et al. Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response. Am J Respir Crit Care Med 1997;155:18351840.
  • 11
    Fahy JV, Fleming HE, Wong HH, Liu JT, Su JQ, Reimann J et al. The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med 1997;155:18281834.
  • 12
    Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001;108:184190.
  • 13
    Milgrom H, Fick RB Jr, Su JQ, Reimann JD, Bush RK, Watrous ML et al. Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group. N Engl J Med 1999;341:19661973.
  • 14
    Soler M, Matz J, Townley R, Buhl R, O’Brien J, Fox H et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001; 18:254261.
  • 15
    Humbert M, Beasley R, Ayres J, Slavin R, Hebert J, Bousquet J et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005; 60:309316.
  • 16
    Djukanovic R, Wilson SJ, Kraft M, Jarjour NN, Steel M, Chung KF et al. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med 2004; 170:583593.
  • 17
    Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl 1993;16:540.
  • 18
    Sterk PJ, Fabbri LM, Quanjer PH, Cockcroft DW, O’Byrne PM, Anderson SD et al. Airway responsiveness. Standardized challenge testing with pharmacological, physical and sensitizing stimuli in adults. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl 1993;16:5383.
  • 19
    Hochhaus G, Brookman L, Fox H, Johnson C, Matthews J, Ren S et al. Pharmacodynamics of omalizumab: implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthma. Curr Med Res Opin 2003;19:491498.
  • 20
    Fahy JV, Liu J, Wong H, Boushey HA. Cellular and biochemical analysis of induced sputum from asthmatic and from healthy subjects. Am Rev Respir Dis 1993;147:11261131.
  • 21
    In‘t Veen JC, De Gouw HW, Smits HH, Sont JK, Hiemstra PS, Sterk PJ et al. Repeatability of cellular and soluble markers of inflammation in induced sputum from patients with asthma. Eur Respir J 1996;9:24412447.
  • 22
    Cockcroft DW, Murdock KY, Kirby J, Hargreave F. Prediction of airway responsiveness to allergen from skin sensitivity to allergen and airway responsiveness to histamine. Am Rev Respir Dis 1987;135:264267.
  • 23
    Sont JK, Willems LN, Evertse CE, Hooijer R, Sterk PJ, Van Krieken JH. Repeatability of measures of inflammatory cell number in bronchial biopsies in atopic asthma. Eur Respir J 1997; 10:26022608.
  • 24
    Sont JK, De Boer WI, Van Schadewijk WA, Grunberg K, Van Krieken JH, Hiemstra PS et al. Fully automated assessment of inflammatory cell counts and cytokine expression in bronchial tissue. Am J Respir Crit Care Med 2003;167:14961503.
  • 25
    Fahy JV, Cockcroft DW, Boulet LP, Wong HH, Deschesnes F, Davis EE et al. Effect of aerosolized anti-IgE (E25) on airway responses to inhaled allergen in asthmatic subjects. Am J Respir Crit Care Med 1999;160:10231027.
  • 26
    Plewako H, Arvidsson M, Petruson K, Oancea I, Holmberg K, Adelroth E et al. The effect of omalizumab on nasal allergic inflammation. J Allergy Clin Immunol 2002;110:6871.
  • 27
    Noga O, Hanf G, Kunkel G. Immunological and clinical changes in allergic asthmatics following treatment with omalizumab. Int Arch Allergy Immunol 2003;131:4652.
  • 28
    Lambrecht BN. Dendritic cells and the regulation of the allergic immune response. Allergy 2005;60:271282.
  • 29
    Lechmann M. CD83 on dendritic cells: more than just a marker for maturation. Trends Immunol 2002;23:273275.
  • 30
    Geijtenbeek TB. Identification of DC-SIGN, a novel dendritic cell-specific ICAM-3 receptor that supports primary immune responses. Cell 2000;100:575585.
  • 31
    Wenzel SE, Fowler AA III, Schwartz LB. Activation of pulmonary mast cells by bronchoalveolar allergen challenge. In vivo release of histamine and tryptase in atopic subjects with and without asthma. Am Rev Respir Dis 1988;137:10021008.
  • 32
    Bateman ED, Hurd SS, Barnes PJ, Bousquet J, Drazen JM, FitzGerald M. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J 2008;31:143178.
  • 33
    Leckie MJ, Ten Brinke A, Khan J, Diamant Z, O’connor BJ, Walls CM et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000;356:21442148.
  • 34
    Birrell MA, Battram CH, Woodman P, McCluskie K, Belvisi MG. Dissociation by steroids of eosinophilic inflammation from airway hyperresponsiveness in murine airways. Respir Res 2003;4:3.
  • 35
    Van Rensen EL, Straathof KC, Veselic-Charvat MA, Zwinderman AH, Bel EH, Sterk PJ. Effect of inhaled steroids on airway hyperresponsiveness, sputum eosinophils, and exhaled nitric oxide levels in patients with asthma. Thorax 1999;54:403408.
  • 36
    Sont JK, Willems LNA, Bel EH, Van Krieken HJM, Vandenbroucke JP, Sterk PJ et al. Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. Am J Resp Crit Care Med 1999;159:10431051.